|
The Drug Safety Newsletter (DSN), Volume 2, Issue 2, 2009 is now available at:
http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/default.htm
DSN is published online quarterly, and provides information for healthcare professionals about the findings of selected post-marketing drug safety reviews, important emerging drug safety issues, and recently approved new drugs. The newsletter is intended to complement other FDA methods of communicating drug safety information to the public. FDA also hopes the newsletter will raise awareness of reported adverse events, and stimulate additional adverse event reporting by healthcare professionals.
Post-Market Reviews include:
- Quinine (Marketed as Qualaquin) Overview of off-label use and serious adverse events
- Zolendronic Acid (Marketed as Reclast) Reports of acute renal impairment and failure associated with once-yearly intravenous treatment for osteoporosis in postmenopausal women
- Arginine Hydrochloride Injection (Marketed as R-Gene 10) Reports of medication errors and adverse events in a pediatric population
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
